We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Wilmington, DE-based Incyte Corporation (INCY - Free Report) is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics.
Incyte’s lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved for the treatment of patients with polycythemia vera (PV), patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. Incyte continues to gain traction by Jakafi’s performance. Jakafi sales are being driven by patient demand. The company is also working to expand the drug’s label.
While Jakafi sales and royalties are a key component of Incyte’s revenue growth, Iclusig sales and Olumiant royalties are also contributing to the top line. In February 2017, the European Commission approved Olumiant for patients with rheumatoid arthritis.
Incyte’s earnings track record has been mixed so far. Of the last four quarters, the company surpassed expectations in three and missed estimates in one. Overall, Incyte delivered an average positive surprise of 42.9%.
Incyte Corporation Price, Consensus and EPS Surprise
Currently, Incyte has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Our consensus called for a loss of 52 cents, while the company reported a loss of 71 cents.
Revenue: Incyte Pharma posted revenues of $444.2 million which beat our consensus estimate of $326.5 million.
Key Stats: Jakafi sales came in at $302 million, up 27% from a year ago. Iclusig revenues were $19 million, up from $13 million in the year-ago quarter.
Check back later for our full write up on this INCY earnings report later!
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Incyte (INCY) Beats on Sales in Q4
Wilmington, DE-based Incyte Corporation (INCY - Free Report) is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics.
Incyte’s lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved for the treatment of patients with polycythemia vera (PV), patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. Incyte continues to gain traction by Jakafi’s performance. Jakafi sales are being driven by patient demand. The company is also working to expand the drug’s label.
While Jakafi sales and royalties are a key component of Incyte’s revenue growth, Iclusig sales and Olumiant royalties are also contributing to the top line. In February 2017, the European Commission approved Olumiant for patients with rheumatoid arthritis.
Incyte’s earnings track record has been mixed so far. Of the last four quarters, the company surpassed expectations in three and missed estimates in one. Overall, Incyte delivered an average positive surprise of 42.9%.
Incyte Corporation Price, Consensus and EPS Surprise
Incyte Corporation Price, Consensus and EPS Surprise | Incyte Corporation Quote
Currently, Incyte has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Our consensus called for a loss of 52 cents, while the company reported a loss of 71 cents.
Revenue: Incyte Pharma posted revenues of $444.2 million which beat our consensus estimate of $326.5 million.
Key Stats: Jakafi sales came in at $302 million, up 27% from a year ago. Iclusig revenues were $19 million, up from $13 million in the year-ago quarter.
Check back later for our full write up on this INCY earnings report later!
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>